Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CUL4A | Q13619 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13552201 | 0.80 | CES1 (0.47) | CUL4APSMB5CES1PSMB1GAA | |
| SCHEMBL17512273 | 0.76 | HDAC6 (0.45) | PSMB5ALDH1A1 | |
| SCHEMBL24803269 | 0.74 | GRIN2B (0.42) | KRAS | |
| SCHEMBL16144682 | 0.74 | CASP3 (0.42) | PSMB5GAAALDH1A1 | |
| SCHEMBL2536105 | 0.73 | PIK3CD (0.40) | GAAALDH1A1 | |
| SCHEMBL13837758 | 0.72 | GSK3A (0.45) | ALDH1A1 | |
| SCHEMBL21218000 | 0.71 | SMN1; SMN2 (0.51) | PSMB5PSMB1GAAALDH1A1 | |
| SCHEMBL18186968 | 0.70 | ACACB (0.39) | GAA | |
| SCHEMBL27151182 | 0.70 | ALDH1A1 (0.56) | ALDH1A1 | |
| SCHEMBL20705071 | 0.70 | HSP90AA1 (0.31) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184549-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-07-19 | — | — | US | disclosed |
| US-20120108579-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8138178-B2 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8114868-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-02-14 | — | — | US | disclosed |
| US-20110021512-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. | 2011-01-27 | — | — | US | disclosed |
| US-20110009402-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021512-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD11B2, HSD3B1 | CUL4A 4313/4885PSMB5 378/4885CES1 50/4885 |
| US-20120108579-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | CUL4A 4301/4885PSMB5 514/4885CES1 41/4885 |
| US-20120184549-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | CUL4A 4489/4885PSMB5 474/4885CES1 64/4885 |
| US-20110009402-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD11B2, HSD3B1 | CUL4A 4476/4885PSMB5 473/4885CES1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.